SCHEMBL4616686

SCHEMBL4616686

COC(=O)C(NC(=O)c1c(O)c(-c2ccccc2)nc2ccccc12)c1cc[n+]([O-])cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 18/20 0.58
TACR2 P21452 6/20 0.58
CYP1A2 P05177 2/20 0.58
CYP3A4 P08684 2/20 0.58
CYP2D6 P10635 2/20 0.58
CYP2C9 P11712 2/20 0.58
TACR1 P25103 1/20 0.58
CYP2C19 P33261 1/20 0.58
OPRM1 P35372 1/20 0.58
TSHR P16473 2/20 0.53
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 1/20 0.53
ALDH1A1 P00352 1/20 0.53
NFKB1 P19838 1/20 0.53
MTOR P42345 1/20 0.53
BLM P54132 1/20 0.53
PMP22 Q01453 1/20 0.53
KMT2A Q03164 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
HSD17B10 Q99714 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6450095 0.92 TACR3 (0.67) TACR3TACR2CYP1A2CYP3A4CYP2D6
SCHEMBL6450103 0.92 TACR3 (0.67) TACR3TACR2CYP1A2CYP3A4CYP2D6
SCHEMBL5113264 0.91 TACR3 (0.56) TACR3TACR2CYP1A2CYP3A4CYP2D6
SCHEMBL5103809 0.90 TACR3 (0.58) TACR3TACR2CYP1A2CYP3A4CYP2D6
SCHEMBL5112779 0.90 TACR3 (0.58) TACR3TACR2CYP1A2CYP3A4CYP2D6
SCHEMBL5106476 0.89 TACR3 (0.62) TACR3TACR2CYP1A2CYP3A4CYP2D6
SCHEMBL4602492 0.88 TACR3 (0.60) TACR3TACR2CYP1A2CYP3A4CYP2D6
SCHEMBL4618529 0.86 TACR3 (0.53) TACR3TACR2CYP1A2CYP3A4CYP2D6
SCHEMBL14015160 0.85 TACR3 (0.62) TACR3TACR2CYP1A2CYP3A4CYP2D6
SCHEMBL4601750 0.83 TACR3 (0.59) TACR3TACR2CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280949-A1 Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators ASTRAZENECA AB (SE) 2008-11-13 US claimed
US-20080280949-A1 Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators ASTRAZENECA AB (SE) 2008-11-13 US disclosed
US-20080280949-A1 Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators ASTRAZENECA AB (SE) 2008-11-13 US disclosed
EP-1915363-A1 OXOPYRIDYL QUINOLINE AMIDES AS NK3 RECEPTOR MODULATORS AstraZeneca AB (SE) 2008-04-30 EP disclosed
WO-2007018469-A1 OXOPYRIDYL QUINOLINE AMIDES AS NK3 RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280949-A1 Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators KCNA3, KCNQ3, GPR3 TACR3 8/4885TACR2 6/4885CYP1A2 930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.